USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: VM DISCOVERY, INC.
City: FREMONT
State: CA
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $504,180.00 3
SBIR Phase II $1,969,090.00 2

Award List:

Multi-Property Design Selective PKC_epsilon Inhibitors

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jie Q. Wu
Award Amount: $98,153.00
Abstract:
DESCRIPTION (provided by applicant): Protein kinase C inhibitors have been rendered as attractive targets for therapeutic agents. Recent studies have been shown that PKC epsilon isozyme is a valid new therapeutic target for treating alcoholism, anxiety and pain related to inflammation and alcoholic… More

Preclinical Development of Selective PKC_epsilon Inhibitors to Treat Alcoholism

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Jay J. Wu
Award Amount: $996,318.00
Abstract:
DESCRIPTION (provided by applicant): Alcoholism and alcohol abuse are the most common forms of drug abuse and effect about 8% of the U.S. population at a cost of approximately 184 billion a year. Current treatment generally consists of psychosocial therap ies aimed at rehabilitation and reducing… More

Not Available

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Patrick Mcdonough
Award Amount: $207,803.00
Abstract:
Breast cancer is a devastating affliction in Western Society. It is of high interest to quantify the expression of  HER2/neu (a growth factor receptor), the estrogen receptor (ER), and the progesterone receptor (PR) in  breast cancer tumors since HER2/neu expression is associated with high… More

DEVELOPMENT OF ANTI-CANCER AGENTS.

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jay Wu
Award Amount: $198,224.00
Abstract:
The overall objective of this proposal is to preclinically develop VMD-1201 or a lead analog compound of a preferentially peripheral-acting PKC epsilon inhibitor as an oral targeted anticancer drug for treatment of human head and neck cancer with much reduced side effects. The long term goal of this… More

Preclinical Development of Selective PKC_epsilon Inhibitors to Treat Alcoholism

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Jay J. Wu – 510-818-1018
Award Amount: $972,772.00
Abstract:
DESCRIPTION (provided by applicant): Alcohol abuse and alcoholism (alcohol use disorders) are significant public health issues and represent one of the largest public health problems. In the United States alone, alcohol use disorders affect about 14 million people, costing approximately 184 billion… More